Skip to main content Skip to search Skip to main navigation

EC: Long-awaited EU Annex 1 on Sterile Manufacturing Published

The long-awaited final version of the new EU Annex 1 "Manufacture of Sterile Medicinal Products" was published on 25 August 2022. The deadline for entry into force is 25 August 2023. Regarding section 8.123 on freeze-drying and product transfer, the deadline for entry into force is two years from now and will thus become mandatory on 25 August 2024:

    8.123 Lyophilizers and associated product transfer and loading/unloading areas should be designed to minimize operator intervention as far as possible. The frequency of lyophilizer sterilisation should be determined based on the design and risks related to system contamination during use. Lyophilizers that are manually loaded or unloaded with no barrier technology separation should be sterilised before each load. For lyophilizers loaded and unloaded by automated systems or protected by closed barrier systems, the frequency of sterilisation should be justified and documented as part of the CCS.

Following two draft documents published in 2017 and 2020, over 6000 comments and much speculation about the final publication date, it is finally here: the new Annex 1 of the EU GMP Guide on Sterile Manufacturing.
With 58 pages, the document has grown in size by another six pages, but its basic structure into eleven areas has remained the same. Among these, the topics of isolators and RABS (4.18) and the section on "Form-Fill-Seal (FFS)" (8.96) are mainly to be mentioned. Isolators and RABS have been subdivided into independent sections and further deepened, which also applies to the topic of FFS, which has been significantly expanded.

Stay in the loop:
We will publish more detailed and comprehensive information on the final Annex 1 in our newsletter LOGFILE as of next week.


Source:

EC: Annex 1 on Manufacture of Sterile Medicinal Products

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

What is the Importance of Data Integrity?

What is the Importance of Data Integrity?

Here's the answer:
Read more
The ABC of User Requirements Specification (URS)

The ABC of User Requirements Specification (URS)

In the URS, the future user defines what the system should be capable of, but also what it is limited to. In addition to the (testable!) technical requirements, regulatory require-ments should also be taken into account.
Read more
EMA: Public Consultation of Annexes to ICH Q3C and VICH GL18 on Residual Solvents

EMA: Public Consultation of Annexes to ICH Q3C and VICH GL18 on Residual Solvents

The European Medicines Agency (EMA) has published revised annexes to the ICH Q3C guideline (“Impurities: Guideline for Residual Solvents”) and the corresponding veterinary guideline VICH GL18 for public consultation. The commenting period is open until the end of June 2026.
Read more
EDQM: Updated Guideline on CEP Revisions and Renewals

EDQM: Updated Guideline on CEP Revisions and Renewals

The European Directorate for the Quality of Medicines & HealthCare has published a revised version of its guideline on the revision and renewal of Certificates of Suitability (CEPs) (PA/PH/CEP (04) 02), aligning it with recent EU legislation on variation procedures.
Read more
FDA: New Draft Guidance on Impurity Specifications for Antibiotics

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

The US FDA has issued a new draft guidance (April 2026) on Impurity Specifications for Antibiotics.
Read more
EDQM: Guidance on Traceability of Medicines in Hospitals

EDQM: Guidance on Traceability of Medicines in Hospitals

The EDQM has published new guidance on the traceability of medicines in hospital settings. The aim is to improve traceability up to the point of administration and strengthen patient safety.
Read more
Previous
Next